Core Insights - Cencora is enhancing its third-party logistics (3PL) capabilities in the United States and Europe to support the growing demand for specialty pharmaceuticals and comprehensive drug supply management [1] Group 1: Expansion in Europe - Cencora is expanding its logistics capabilities in Europe by acquiring NextPharma Logistics, which operates in Germany, Austria, and Switzerland [1] - A new 3PL facility is planned to open in Italy in 2026, complementing recent investments in storage capacity in France, Spain, and the UK [1] - The addition of NextPharma Logistics and the new facility in Italy will enhance Cencora's ability to provide comprehensive pan-European support [1] Group 2: Expansion in the United States - Cencora plans to open a highly automated 500,000 square-foot 3PL facility in Texas by 2028, which will be its fifth 3PL facility in the U.S. [1] - The new Texas facility will significantly increase Cencora's capacity for storing products at controlled room temperature, refrigerated, and frozen ranges, including ultra-low and cryogenic storage [1] - Cencora has more than tripled its ultra-low and cryogenic storage capacity across its U.S. 3PL network to accommodate the rising number of specialty medicines, such as cell and gene therapies [1] Group 3: Strategic Positioning - Cencora aims to provide integrated support for pharmaceutical companies navigating supply chain complexities and maximizing commercial success [1] - The company is uniquely positioned to support pharmaceutical companies' needs for comprehensive logistics solutions across multiple markets [1] - Cencora's global specialty logistics capabilities enable it to offer support from clinical trials through commercialization, including tailored supply chain solutions for cell and gene therapies [1] Group 4: Company Overview - Cencora is a leading global pharmaceutical solutions organization with over 51,000 team members and more than $300 billion in annual revenue [2] - The company is ranked 10 on the Fortune 500 and 18 on the Global Fortune 500 [2]